Skip to Content

Join the 'Natrecor' group to help and get support from people like you.

Natrecor News

Bystander CPR Linked to Better Outcomes After Cardiac Arrest

Posted 4 May 2015 by Drugs.com

MONDAY, May 4, 2015 – New research from Denmark finds that more cardiac arrest survivors are returning to work, because more bystanders are performing CPR. "We already know CPR helps save lives – and now our findings suggest there is even more benefit in performing it," study author Dr. Kristian Kragholm, a clinical assistant at Aalborg University Hospital and Aarhus University in Aalborg, said in an American Heart Association (AHA) news release. He is also a fellow at the Duke Clinical Research Institute in Durham, N.C. For the new study, researchers tracked over 4,300 people in Denmark who had jobs prior to experiencing cardiac arrest between 2001 and 2011. The study only included people who were not in a hospital at the time of their cardiac arrest. More than 75 percent of the survivors were capable of returning to work, and their chances of doing so were about 40 percent higher in ... Read more

Related support groups: Heart Disease, Heart Attack, Minoxidil, Nitroglycerin, Myocardial Infarction, Alprostadil, Hydralazine, Muse, Edex, Caverject, Prevention of Cardiovascular Disease, Nitrostat, Cardiovascular Risk Reduction, Nitro-Bid, Nitro-Dur, NitroQuick, Cardiovascular Conditions and Disorders, Caverject Impulse, Nitrolingual Pumpspray, Adempas

911 Best Call for Heart Attack Victims in Rural Areas: Study

Posted 1 May 2015 by Drugs.com

FRIDAY, May 1, 2015 – Many rural residents with severe heart attacks drive or are driven to the hospital, but they have a better chance of survival if they call 911, a new study finds. Researchers looked at 774 people in rural Minnesota, North Dakota and South Dakota who suffered a severe type of heart attack in 2013 and 2014. Fifty-two percent of them arrived at the hospital in their own vehicles, rather than calling 911. The average time it took to get to the hospital was 38 minutes for patients who traveled in their own vehicles and 26 minutes for those brought by ambulance. The average time it took from arriving at the hospital to receiving heart artery-opening treatment was 57 minutes for those who traveled in their own vehicles and 42 minutes for those who arrived by ambulance. The study was published April 29 in the American Heart Association (AHA) journal Circulation: ... Read more

Related support groups: Heart Attack, Minoxidil, Nitroglycerin, Myocardial Infarction, Hydralazine, Alprostadil, Muse, Edex, Caverject, Nitrostat, Nitro-Bid, Nitro-Dur, NitroQuick, Caverject Impulse, Diazoxide, Nitrolingual Pumpspray, Edex Refill, Apresoline, Adempas, Nitrostat Tablets

Accidental Medication Poisonings in Kids on the Rise

Posted 16 Sep 2011 by Drugs.com

FRIDAY, Sept. 16 – Despite ongoing prevention efforts, a growing number of young children are being accidentally poisoned with medications, according to new research. The study, which was based on data reported to the American Association of Poison Control Centers between 2001 and 2008, found that medication poisoning among children aged 5 and under increased by 22 percent, although the number of children in the United States in this age group rose by only 8 percent during the study period. "The problem of pediatric poisoning in the U.S. is getting worse, not better," Dr. Randall Bond, of Cincinnati Children's Hospital Medical Center, said in a hospital news release. In conducting the study, which is scheduled for publication in the Journal of Pediatrics, the researchers reviewed information on over 544,000 children who landed in the emergency department due to medication poisoning ... Read more

Related support groups: Xanax, Suboxone, Oxycodone, Hydrocodone, Methadone, Percocet, OxyContin, Klonopin, Vicodin, Lisinopril, Norco, Fentanyl, Clonazepam, Morphine, Ativan, Ambien, Valium, Codeine, Metoprolol, Lortab

Study Finds Heart Failure Drug Ineffective

Posted 6 Jul 2011 by Drugs.com

WEDNESDAY, July 6 – The heart failure drug Natrecor (nesiritide) is ineffective and linked to increased rates of potentially dangerous low blood pressure, a new study finds. The intravenous drug was approved in 2001 to help heart failure patients breathe more easily when they were struggling with severe shortness of breath. But the drug had no significant effect on breathing difficulties or other disease-related problems and may also result in low blood pressure, according to the researchers. The report was published in the July 7 issue of the New England Journal of Medicine. The study "doesn't show any use for nesiritide, that's for sure," said Dr. Eric J. Topol, professor of translational genomics at the Scripps Research Institute in La Jolla, Calif., and author of an accompanying journal editorial. Topol noted nesiritide isn't used much, because it is considered no better than some ... Read more

Related support groups: Heart Failure, Congestive Heart Failure, Natrecor, Nesiritide

FDA Medwatch Alert: Natrecor (nesiritide)

Posted 19 May 2005 by Drugs.com

Scios and FDA notified healthcare professionals of revisions to the ADVERSE REACTIONS/Effect on Mortality section of the prescribing information for Natrecor [nesiritide], indicated for patients with acutely decompensated congestive heart failure. The Dear Healthcare Professional letter also provided information from Scios on several published reports that raise the question of whether the product may have adverse effects on survival and kidney function compared to control agents (generally nitroglycerin and diuretics). [May 6, 2005 - Dear Healthcare Professional Letter - Scios][April, 2005 - Natrecor Label - Scios] Read more

Related support groups: Natrecor

FDA Medwatch Alert: Natrecor (nesiritide)

Posted 18 Jul 2005 by Drugs.com

[Posted 07/18/2005] Scios and FDA notified healthcare professionals about the recommendations of an expert panel of cardiology and heart failure clinicians with regard to NATRECOR (nesiritide). With respect to recent questions raised about worsened renal function and mortality, the panel provided a consensus statement on each issue, provided advice on the ongoing and planned clinical development program, made recommendations about the appropriate use of the drug and recommeded an educational campaign to ensure that clinicians understand when the use of NATRECOR is appropriate and when it is not appropriate.[July 13, 2005 - Read more

Related support groups: Natrecor

Ask a Question

Further Information

Related Condition Support Groups

Heart Failure, Congestive Heart Failure

Natrecor Patient Information at Drugs.com